Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jana Marková, Jana Marková, Zuzana Trnková, Petra Michková, Jacqueline Maaloufová, Jan Starý, Petr Cetkovský & Jiří Schwarz. (2009) Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leukemia & Lymphoma 50:9, pages 1448-1460.
Read now
Read now
Eugenio Lucia, Bruno Martino, Corrado Mammi, Ernesto Vigna, Carla Mazzone, Massimo Gentile, Gabriele Qualtieri, Maria Grazia Bisconte, Maria Naccarato, Carlo Gentile, Carmelo Laganà, Francesco Romeo, Antonino Neri, Francesco Nobile & Fortunato Morabito. (2008) The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. Leukemia & Lymphoma 49:10, pages 1907-1915.
Read now
Read now
Aaron Polliack, Koen van Besien & John F. Seymour. (2008) 2007: The year in review for Leukemia and Lymphoma. Leukemia & Lymphoma 49:1, pages 1-3.
Read now
Read now
Joanne Bareng, Iman Jilani, Mercedes Gorre, Hagop Kantarjian, Francis J. Giles, Alison Hannah & Maher Albitar. (2007) A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leukemia & Lymphoma 48:11, pages 2189-2195.
Read now
Read now
Jana Marková, Dana Průková, Zuzana Volková & Jiří Schwarz. (2007) A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation. Leukemia & Lymphoma 48:3, pages 636-639.
Read now
Read now
Articles from other publishers (35)
Ekaterina Belotserkovskaya, Vasily Golotin, Burhan Uyanik & Oleg N. Demidov. (2023) Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly. Cell Death Discovery 9:1.
Crossref
Crossref
Rachel B. Salit. (2022) The role of JAK inhibitors in hematopoietic cell transplantation. Bone Marrow Transplantation 57:6, pages 857-865.
Crossref
Crossref
Sanam Loghavi & Robert P. Hasserjian. 2018. Diagnosis of Blood and Bone Marrow Disorders. Diagnosis of Blood and Bone Marrow Disorders
17
79
.
Jun Xia, Mi-ze Lu, Yuan-qiang Jiang, Guo-hua Yang, Yun Zhuang, Hong-li Sun & Yun-feng Shen. (2012) JAK2 V617F, MPL W515L and JAK2 exon 12 mutations in Chinese patients with primary myelofibrosis. Chinese Journal of Cancer Research 24:1, pages 72-76.
Crossref
Crossref
Joëlle Rubert, Zhiyan Qian, Rita Andraos, Daniel A Guthy & Thomas Radimerski. (2011) Bim and Mcl-1 exert key roles in regulating JAK2V617Fcell survival. BMC Cancer 11:1.
Crossref
Crossref
Cornelis J.J. Huijsmans, Jeroen Poodt, Paul H.M. Savelkoul & Mirjam H.A. Hermans. (2011) Sensitive Detection and Quantification of the JAK2V617F Allele by Real-Time PCR. The Journal of Molecular Diagnostics 13:5, pages 558-564.
Crossref
Crossref
Tao Wang, Stephanos Ioannidis, Lynsie Almeida, Michael H. Block, Audrey M. Davies, Michelle L. Lamb, David A. Scott, Mei Su, Hai-Jun Zhang, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell & Michael Zinda. (2011) In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:10, pages 2958-2961.
Crossref
Crossref
David R. Head & Katherine S. Hamilton. 2011. Hematopathology. Hematopathology
656
671
.
Wing C. (John) Chan, Timothy C. Greiner & Adam Bagg. 2011. Hematopathology. Hematopathology
56
80
.
Wanlong Ma, Hagop Kantarjian, Xi Zhang, Xiuqiang Wang, Zhong Zhang, Chen-Hsiung Yeh, Susan O'Brien, Francis Giles, Jean Marie Bruey & Maher Albitar. (2010) JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms. PLoS ONE 5:8, pages e12165.
Crossref
Crossref
Meredith A. Lakey, Animesh Pardanani, James D. Hoyer, Phuong L. Nguyen, Terra L. Lasho, Ayalew Tefferi & Curtis A. Hanson. (2010)
Bone Marrow Morphologic Features in Polycythemia Vera With
JAK2
Exon 12 Mutations
. American Journal of Clinical Pathology 133:6, pages 942-948.
Crossref
Crossref
W. MA, H. KANTARJIAN, X. ZHANG, C.‐H. YEH, Z. J. ZHANG, S. VERSTOVSEK, S. O’BRIEN, F. GILES & M. ALBITAR. (2010)
Plasma levels of
JAK2
mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology
. International Journal of Laboratory Hematology 32:1p2, pages 95-102.
Crossref
Crossref
Jason D. Merker, Carol D. Jones, Stephen T. Oh, Iris Schrijver, Jason Gotlib & James L. Zehnder. (2010) Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory. The Journal of Molecular Diagnostics 12:1, pages 58-64.
Crossref
Crossref
Mike Perez & Chung-Che (Jeff) Chang. 2010. Molecular Pathology of Hematolymphoid Diseases. Molecular Pathology of Hematolymphoid Diseases
395
403
.
Hans Michael Kvasnicka & Juergen Thiele. (2009) Prodromal myeloproliferative neoplasms: The 2008 WHO classification. American Journal of Hematology 85:1, pages 62-69.
Crossref
Crossref
Juergen Thiele. (2009) Philadelphia Chromosome–Negative Chronic Myeloproliferative Disease. American Journal of Clinical Pathology 132:2, pages 261-280.
Crossref
Crossref
Tai-Sung Lee, Wanlong Ma, Xi Zhang, Francis Giles, Hagop Kantarjian & Maher Albitar. (2009) Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer 115:8, pages 1692-1700.
Crossref
Crossref
Hans Michael Kvasnicka & Juergen Thiele. (2009) Diagnosis of chronic myeloproliferative neoplasms with special emphasis on early stages. Diagnostic Histopathology 15:3, pages 125-133.
Crossref
Crossref
Juergen Thiele & Hans Michael Kvasnicka. (2008) The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Current Hematologic Malignancy Reports 4:1, pages 33-40.
Crossref
Crossref
Su-jiang ZHANG & Jian-yong LI. (2008) An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era. Chinese Medical Journal 121:18, pages 1838-1842.
Crossref
Crossref
Hui-Hua Hsiao, Wen-Chi Yang, Yi-Chang Liu, Ching-Ping Lee & Sheng-Fung Lin. (2008) Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. Leukemia Research 32:8, pages 1323-1324.
Crossref
Crossref
Cristina A. Smith & Guang Fan. (2008) The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Human Pathology 39:6, pages 795-810.
Crossref
Crossref
A Wickrema & J D Crispino. (2007) Erythroid and megakaryocytic transformation. Oncogene 26:47, pages 6803-6815.
Crossref
Crossref
Juergen Thiele, Attilio Orazi & Hans Kvasnicka. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders
19
50
.
Anna D. Panani. (2007) Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications. Cancer Letters 255:1, pages 12-25.
Crossref
Crossref
Natarajan V. Bhanu, Wulin Aerbajinai, Nicole M. Gantt, Edwin K. Jackson, Sung-Ho Goh, Y. Terry Lee & Jeffery L. Miller. (2007) Cl-IB-MECA inhibits human erythropoiesis. British Journal of Haematology 137:3, pages 233-236.
Crossref
Crossref
Kenneth Kaushansky. (2007) The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age. Best Practice & Research Clinical Haematology 20:1, pages 5-12.
Crossref
Crossref
Hajnalka Andrikovics, Anikó Szilvási, Nóra Meggyesi, Viktória Király, Gabriella Halm, Sándor Lueff, Sarolta Nahajevszky, Gábor Mikala, Andrea Sipos, Nóra Lovas, Zoltán Csukly, Zoltán Mátrai, Júlia Tamáska, Attila Tordai & Tamás Masszi. (2007) Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection. Orvosi Hetilap 148:5, pages 203-210.
Crossref
Crossref
S Verstovsek, R T Silver, N C P Cross & A Tefferi. (2006) JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. Leukemia 20:11, pages 2067-2067.
Crossref
Crossref
David P. Steensma. (2006) JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility. The Journal of Molecular Diagnostics 8:4, pages 397-411.
Crossref
Crossref
Chung-Che(Jeff) Chang. (2006)
BCR/ABL
-Negative Chronic Myeloproliferative Disorders:
JAK2
Mutation and Beyond
. Archives of Pathology & Laboratory Medicine 130:8, pages 1123-1125.
Crossref
Crossref
Asim Khwaja. (2006) The role of Janus kinases in haemopoiesis and haematological malignancy. British Journal of Haematology 134:4, pages 366-384.
Crossref
Crossref
Lambros K. Bourantas, Anthoula Chatzikyriakidou, Aggeliki Dasoula, Marika Syrrou, Konstantinos L. Bourantas & Ioannis Georgiou. (2006) Absence of mutations of the EPO-receptor gene in Greek patients with familiar polycythemia. European Journal of Haematology 76:6, pages 537-538.
Crossref
Crossref
D P Steensma, R F McClure, J E Karp, A Tefferi, T L Lasho, H L Powell, G W DeWald & S H Kaufmann. (2006) JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 20:6, pages 971-978.
Crossref
Crossref
J. Brière. (2006) Thrombocytémie essentielle. Critères du diagnostic. Stratification pronostique. Ébauche de stratégie thérapeutique. EMC - Hématologie 1:3, pages 1-19.
Crossref
Crossref